Literature DB >> 18579277

Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.

Norio Yasui-Furukori1, Manabu Saito, Shoko Tsuchimine, Taku Nakagami, Yasushi Sato, Norio Sugawara, Sunao Kaneko.   

Abstract

Hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. Recent studies have suggested that polymorphisms of the dopamine receptors are associated with therapeutic response to antipsychotics. Thus, we studied the effects of major polymorphisms of dopamine-related genes on plasma concentration of prolactin. Subjects were 174 schizophrenic patients (68 males, 106 females) receiving 3 mg twice daily of risperidone for at least 4 weeks. Sample collections were conducted 12 h after the bedtime dosing. Five dopamine-related polymorphisms (Taq1A, -141C ins/del for DRD2, Ser9Gly for DRD3, 48 bp VNTR for DRD4, Val158Met for COMT) were identified. The mean (+/-SD) plasma concentration of prolactin in females was significantly higher than males (54.3+/-27.2 ng/ml versus 126.8+/-70.2 ng/ml, p<0.001). No dopamine-related polymorphisms differed the plasma concentration of prolactin in males or females. Multiple regression analyses including plasma drug concentration and age revealed that plasma concentration of prolactin correlated with gender (standardized partial correlation coefficients (beta)=0.551, p<0.001) and negatively with age (standardized beta=-0.202, p<0.01). No correlations were found between prolactin concentration and dopamine-related polymorphisms. These findings suggest that plasma prolactin concentrations in females are much higher than in males but the dopamine-related variants are not predominantly associated with plasma concentration of prolactin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579277     DOI: 10.1016/j.pnpbp.2008.05.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

1.  Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome.

Authors:  Lori D Hill; Kathryn G Ewens; Brion S Maher; Timothy P York; Richard S Legro; Andrea Dunaif; Jerome F Strauss
Journal:  Mol Cell Endocrinol       Date:  2011-12-08       Impact factor: 4.102

2.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

3.  Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.

Authors:  Chadi A Calarge; Vicki L Ellingrod; Laura Acion; Del D Miller; Jessica Moline; Michael J Tansey; Janet A Schlechte
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

Review 4.  Pharmacogenetics of antipsychotic-induced side effects.

Authors:  Todd Lencz; Anil K Malhotra
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

5.  Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone.

Authors:  Yaowaluck Hongkaew; Nattawat Ngamsamut; Apichaya Puangpetch; Natchaya Vanwong; Pornpen Srisawasdi; Montri Chamnanphon; Bhunnada Chamkrachchangpada; Teerarat Tan-Kam; Penkhae Limsila; Chonlaphat Sukasem
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-22       Impact factor: 2.570

Review 6.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

Review 7.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

8.  Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia.

Authors:  Jiyang Han; Yan Li; Xumei Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-12-05       Impact factor: 2.570

9.  Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia.

Authors:  Charanraj Goud Alladi; Anbarasan Mohan; Deepak Gopal Shewade; Ravi Philip Rajkumar; Surendiran Adithan; Karthick Subramanian
Journal:  J Pharmacol Pharmacother       Date:  2017 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.